Little Rock, AR – Following the successful completion of Phase 1 clinical safety evaluation for the novel anti-methamphetamine antibody IXT-m200 (ch-mAb7F9), InterveXion has announced plans to continue clinical development of this agent. The STAMPOUT study will be a Phase 2a, parallel-group, placebo-controlled, double-blind study of the effect of IXT-m200 on methamphetamine pharmacokinetics and subjective effects in methamphetamine users. InterveXion received a positive response to questions submitted to FDA concerning the STAMPOUT protocol with a short list of Division-requested updates or clarifications. All requests were feasible within the current study design and will be addressed in the final protocol. InterveXion has submitted an NIH grant application to fund this proof-of-concept study and hopes to begin in Q1-2018.
- InterveXion Enrolls First Patient in Phase 2 Study of the Effect of IXT-m200 on Methamphetamine PK and PD
- InterveXion Licenses Asian Rights to Novel Anti-Methamphetamine Antibody to Ascent Therapeutics
- InterveXion Awarded $8M to Fund Phase 2 Clinical Study of Anti-Methamphetamine Medication
- STAMPOUT study to be conducted in METH users when funded
- InterveXion Therapeutics Announces Fast Track Designation of IXT-m200 for Treatment of Methamphetamine Addiction